Year: 2017
Development and Verification of PBPK Model for a Topical Cream Formulation of Trifarotene to Simulate Local and Systemic Exposure and Model Application to Simulate Potential CYP-mediated Drug-drug Interactions
Reference-scaled Average Bioequivalence (RSABE) Approach for Drugs with a Narrow Therapeutic Index (NTID) Using Phoenix WinNonlin
D360 Partner
D360 Partner is an affordable add-on product for D360 for external partners that allows for seamless, secure sharing of data and analysis while advancing communication and collaboration.
Certara to Showcase a Wide Range of Modeling and Simulation Advances at AAPS Annual Meeting
PRINCETON, NJ – Nov. 7, 2017 – Certara today announced that it will be participating in 12 sessions at the 2017 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting. This conference will be held from November 12–15 at the San Diego Convention Center in San Diego, CA.
Modeling Alternative Treatment Strategies for Onchocerciasis: Moxidectin for Control and Elimination
The Potential for Six-monthly Mass Administration of Moxidectin to Accelerate Onchocerciasis Elimination
How Can You Get the Most out of Phoenix 8.0?
In this webinar, Dr. Nathan Teuscher demonstrated how to get the most out of Phoenix 8.0’s new features, including how to automatically calculate new NCA parameters, set up parallelization of Phoenix NLME runs, and leverage the new validation suite to get up and running in no time.
Exposure-response of Veliparib to Inform Phase 2 Trial Design in Refractory or Relapsed Patients with Hematological Malignancies
Simcyp Simulator Version 17 Features
Learn about the new features incorporated into the latest release of the Simcyp Population-based Simulator, which streamlines drug development through the modeling and simulation of pharmacokinetics and pharmacodynamics in virtual populations.